focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 69.00
Bid: 68.00
Ask: 70.00
Change: 0.00 (0.00%)
Spread: 2.00 (2.941%)
Open: 69.00
High: 69.00
Low: 69.00
Prev. Close: 69.00
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wanda Technology Enhancements

18 Jul 2018 07:00

RNS Number : 9050U
NetScientific PLC
18 July 2018
 

 

 

NetScientific plc

("NetScientific" or the "Company" or the "Group")

 

Portfolio Company, Wanda Enhances Remote Patient Monitoring Platform with Improved Patient Adherence Features

 

London, UK - July 18th, 2018 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that portfolio company Wanda, which uses machine learning to help healthcare providers to better manage the risk and care of patients, has completed a significant enhancement of its Patient Management Platform to improve patient adherence to care plans. Use of Wanda's existing platform had been shown to predict 90% of patient-level adverse events up to 7 days in advance of their occurrence, and allows for virtual intervention to prevent such events.

 

The new enhanced Patient Reminder Suite empowers clinicians to better engage patients in care plan adherence through personalised reminders and alerts, which can be pre-scheduled and delivered via multi-modal communications. The enhancements also include the adoption of the Cloud Text-to-Speech Application Programming Interface from Google that uses machine learning to deliver natural-sounding human voice automation. The combined effect of the enhanced reminder tools, the early prediction of adverse events, and the virtual intervention insight gives providers a highly intelligent method to defend against the costs of unplanned readmissions and emergency department visits due to nonadherence.

 

Commenting on the news, Francois R. Martelet, NetScientific's Chief Executive Officer and Chairman of Wanda, said: "Wanda's enhancements to its core technology mean that relationships between clinicians and patients will continue to improve, and will empower patients to take a more active role in the management of their diseases as well as increase their quality of life. We continue to see invaluable potential in Wanda and look forward to monitoring its progress in the coming months."

 

NetScientific holds a 62% stake on a fully diluted basis in Wanda.

 

For more information, please contact:

 

  NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO

Tel: +44 (0)20 3514 1800

Wanda, Inc.

Bill Basset, CCO

Tel: +1 (0)206 910 0428

 

Consilium Strategic Communications

Mary-Jane Elliott / Chris Welsh / Laura Thornton

 

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

Stifel Nicolaus Europe Limited (NOMAD and Broker)

Jonathan Senior / David Arch / Ben Maddison

 Tel: +44 (0) 20 7710 7600

 

 

About NetScientific

 

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

 

 

Wanda Expands Patient Management Platform with Enhanced Patient Adherence Features

San Francisco, CA - July 18th, 2018 - Wanda, Inc. announces a significant expansion of their market-leading Patient Management Platform with expansive new features to further improve patient care plan adherence. The Wanda solution, embedded with clinically proven machine learning, predicts 90% of patient-level adverse events seven days before they occur and then facilitates virtual interventions to keep them from occurring. The enhanced Patient Reminder Suite empowers clinicians to better engage patients in care plan adherence through personalized reminders and alerts, which can be pre-scheduled and delivered via multi-modal communications. The enhancements also include the adoption of the Cloud Text-to-Speech API from Google that uses machine learning to deliver natural-sounding human voice automation.

The combined effect of the enhanced reminder tools, the early prediction of adverse events, and the virtual intervention insight gives providers a highly intelligent method to defend against the costs of unplanned readmissions and emergency department visits due to nonadherence. Depending on the complexity of the care plan, as many as 40% of patients fail to adhere to treatment plans.1 Between $100 and $300 billion in avoidable health care costs have been attributed to non-adherence in the US annually, representing 3%-10% of total US healthcare costs.2

"Healthcare providers have been pleased with how the Wanda platform has positively impacted the relationship between patients and their clinical care teams. The clinicians are able better deliver on their mission to provide great care with meaning and timely insight. Patients are more engaged and in control of the care", stated William Bassett, Chief Commercialization Officer of Wanda, Inc.

A key driver in patient non-adherence is related to medications with adherence rates dropping to 20% for patients that are required to take thirteen or more medications per day.3 Patient non-adherence can be corrected by the patient with the appropriate support. The leading reason for non-adherence most commonly reported was forgetfulness by the patient.4 The Patient Reminder Suite in Wands is specifically designed help clinicians easily create, personalize, and schedule reminders for all types of care support needs including medication reminders, vitals, daily symptom survey questions, pending visits to the doctor or at home visits, and prompts to exercise. For patients that prefer to interact with Wanda using the interactive voice response model, the inclusion of the Google voice technology provides a warm sounding human voice adding even more satisfaction to the patient interaction.

"Wanda continues to expand on its mission to fuse cutting edge data science with clinical care management to solve the major roadblocks in care models," said Ahsan Samiee, Chief Technology Officer, Wanda, Inc. "The financial and clinical results achieved by customers continue to validate our belief that these approaches should be imbued across healthcare for the betterment of all."

 

1, 3. Martin L, Williams S, Haskard, DiMatteo M. 2005. The Challenge of Patient Adherence. Therapeutics and Clinical Risk Management. 2005; 189-199.

2, 4. Iuga A, McGuire M. 2014. Adherence and Health Care Costs. Risk Management and Healthcare Policy. 2104; 35-44.

 

About Wanda, Inc.

Wanda is dedicated to advancing the effectiveness and efficiency of medicine by using machine learning and modern software applications that empower payers and providers to better manage the risk and care of patients dramatically lowering the cost of care and improving outcomes. More information about Wanda can be found at http://www.yourwanda.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABBGDRRGBBGIR
Date   Source Headline
27th May 20214:36 pmRNSPrice Monitoring Extension
24th May 20217:00 amRNSProAxsis Update
21st May 202111:00 amRNSPrice Monitoring Extension
20th May 20214:19 pmRNSPDS Announces Release of PDS0101 Abstract
20th May 20217:00 amRNSEMV Capital Advises on £3.4m PointGrab Fundraise
18th May 20217:00 amRNSPDS receives $4.5m from net sale of tax benefits
13th May 20213:15 pmRNSPDS Reports Results for Q1 2021 & Business Update
13th May 20217:00 amRNSEMV Capital Advises on £2.9m SageTech Fundraise
30th Apr 20217:00 amRNSPDS Announces Presentation at ASCO Annual Meeting
28th Apr 202110:08 amRNSEMV Capital Advises on £740k Fundraise for Sofant
14th Apr 20212:25 pmRNSNotice of AGM and Annual Report & Accounts
31st Mar 20219:02 amRNSPreliminary Results for the year ended 31 Dec 2020
30th Mar 20217:00 amRNSNotice of Results & Investor Presentation
18th Mar 202111:48 amRNSPDS Reports Results for FY2020 & Business Update
11th Mar 20213:26 pmRNS$60m Commitment for PDS Vaccine Consortium
23rd Feb 20217:00 amRNSPDS Biotech Consortium Update
22nd Feb 20217:00 amRNSProAxsis Update
10th Feb 202111:01 amRNSPrice Monitoring Extension
10th Feb 20219:05 amRNSSecond Price Monitoring Extn
10th Feb 20219:00 amRNSPrice Monitoring Extension
5th Feb 20214:40 pmRNSSecond Price Monitoring Extn
5th Feb 20214:35 pmRNSPrice Monitoring Extension
5th Feb 20212:06 pmRNSSecond Price Monitoring Extn
5th Feb 20212:01 pmRNSPrice Monitoring Extension
5th Feb 202111:05 amRNSSecond Price Monitoring Extn
5th Feb 202111:00 amRNSPrice Monitoring Extension
3rd Feb 20212:45 pmRNSRestoration - Netscientific plc
3rd Feb 20212:45 pmRNSPDS Phase II Trial Update & Restoration of Trading
2nd Feb 20217:30 amRNSSuspension - Netscientific plc
2nd Feb 20217:00 amRNSSuspension of Trading on AIM
25th Jan 20217:00 amRNSIssue of Shares, Director/PDMR Shareholding & TVR
4th Jan 202110:31 amRNSHolding(s) in Company
21st Dec 20202:59 pmRNSPDS Announces Publication of Data by Mount Sinai
10th Dec 20207:00 amRNSProAxsis awarded Innovate UK grant
7th Dec 202011:05 amRNSSecond Price Monitoring Extn
7th Dec 202011:00 amRNSPrice Monitoring Extension
2nd Dec 20207:00 amRNSBoard changes and Grant of Options
30th Nov 20201:56 pmRNSEMV Capital leads a £1.28m investment in SageTech
19th Nov 20207:00 amRNSProAxsis appoints DiaPharma as distributor
11th Nov 20202:10 pmRNSPDS updates on Versamune based COVID-19 vaccine
10th Nov 202012:47 pmRNSPDS Biotech Initiates VERSATILE-002 Phase 2 Trial
27th Oct 20209:46 amRNSPDS Announces Initiation of PDS0101 Phase 2 Trial
16th Oct 20207:00 amRNSNetScientific acquires 100% of portfolio company
30th Sep 20209:08 amRNSDirector/PDMR Shareholding
30th Sep 20209:07 amRNSHolding(s) in Company
30th Sep 20208:58 amRNSHolding(s) in Company
25th Sep 202012:37 pmRNSGrant of Options to Director
24th Sep 20207:00 amRNSInterim Results
2nd Sep 20207:00 amRNSHolding(s) in Company
2nd Sep 20207:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.